CN Patent

CN115192575A — 使用芬氟拉明治疗Lennox-Gastaut综合征的方法

Assigned to Zogenix International Ltd · Expires 2022-10-18 · 4y expired

What this patent protects

本申请涉及使用芬氟拉明治疗Lennox‑Gastaut综合征的方法。一种在患者(例如先前诊断为患有Lennox综合征的患者)中治疗和/或预防Lennox‑Gastaut综合征(LGS)症状(也被称为Lennox综合征)的方法，通过向该患者给予有效剂量的芬氟拉明或其药学上可接受的盐。以小于约2.0至约0.01mg/kg/天的优选剂量治疗Lennox综合症患者。

USPTO Abstract

本申请涉及使用芬氟拉明治疗Lennox‑Gastaut综合征的方法。一种在患者(例如先前诊断为患有Lennox综合征的患者)中治疗和/或预防Lennox‑Gastaut综合征(LGS)症状(也被称为Lennox综合征)的方法，通过向该患者给予有效剂量的芬氟拉明或其药学上可接受的盐。以小于约2.0至约0.01mg/kg/天的优选剂量治疗Lennox综合症患者。

Drugs covered by this patent

Patent Metadata

Patent number: CN115192575A
Jurisdiction: CN
Classification: —
Expires: 2022-10-18
Drug substance claim: No
Drug product claim: No
Assignee: Zogenix International Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.